Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « AffOrg.i » - entrée « Université de Tokyo »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Université de São Paulo < Université de Tokyo < Université de Toronto  Facettes :

List of bibliographic references indexed by Université de Tokyo

Number of relevant bibliographic references: 29.
[20-40] [0 - 20][0 - 29]
Ident.Authors (with country if any)Title
002867 (2013) Tsutomu Takeuchi [Japon] ; Masayoshi Harigai [Japon] ; Yoshiya Tanaka [Japon] ; Hisashi Yamanaka [Japon] ; Naoki Ishiguro [Japon] ; Kazuhiko Yamamoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Takao Koike [Japon] ; Minoru Kanazawa [Japon] ; Takuya Oba [Japon] ; Toru Yoshinari [Japon] ; Daniel Baker [États-Unis]Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks
002954 (2013) M. Yamamoto ; H. Takahashi ; Y. Naishiro ; T. Tabeya ; K. Ishigami ; Y. Shimizu ; H. Yajima ; M. Matsui ; C. Suzuki ; H. Yamamoto ; S. Honda ; T. Abe ; Y. Suzuki ; T. Himi ; K. Imai [Japon] ; Y. ShinomuraTHU0398 Efficacy of rituximab and other immunosuppressants for IgG4-related disease
003239 (2013) Y. Tanaka ; K. Yamamoto [Japon] ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Eguchi ; A. Watanabe [Japon] ; H. Origasa ; T. Okamoto ; T. Shoji ; N. Miyasaka [Japon] ; T. Koike [Japon]AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort
003572 (2012) Ryoko Sakai [Japon] ; Michi Tanaka [Japon] ; Toshihiro Nanki [Japon] ; Kaori Watanabe [Japon] ; Hayato Yamazaki [Japon] ; Ryuji Koike [Japon] ; Hayato Nagasawa [Japon] ; Koichi Amano [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] ; Satoshi Ito [Japon] ; Takayuki Sumida [Japon] ; Atsushi Ihata [Japon] ; Yoshiaki Ishigatsubo [Japon] ; Tatsuya Atsumi [Japon] ; Takao Koike [Japon] ; Atsuo Nakajima [Japon] ; Naoto Tamura [Japon] ; Takao Fujii [Japon] ; Hiroaki Dobashi [Japon] ; Shigeto Tohma [Japon] ; Takahiko Sugihara [Japon] ; Yukitaka Ueki [Japon] ; Akira Hashiramoto [Japon] ; Atsushi Kawakami [Japon] ; Noboru Hagino [Japon] ; Nobuyuki Miyasaka [Japon] ; Masayoshi Harigai [Japon]Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules
003960 (2011) Kayoko Kaneko [Japon] ; Yoshishige Miyabe [Japon] ; Aiko Takayasu [Japon] ; Shin Fukuda [Japon] ; Chie Miyabe [Japon] ; Masashi Ebisawa [Japon] ; Waka Yokoyama [Japon] ; Kaori Watanabe [Japon] ; Toshio Imai [Japon] ; Kenzo Muramoto [Japon] ; Yuya Terashima [Japon] ; Takahiko Sugihara [Japon] ; Kouji Matsushima [Japon] ; Nobuyuki Miyasaka [Japon] ; Toshihiro Nanki [Japon]Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis
003C55 (2010) Jun Hashimoto [Japon] ; Patrick Garnero [France] ; Désirée Van Der Heijde [Pays-Bas] ; Nobuyuki Miyasaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Shinichi Kawai [Japon] ; Tsutomu Takeuchi [Japon] ; Hideki Yoshikawa [Japon] ; Norihiro Nishimoto [Japon]Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
003F52 (2009) N. Nishimoto [Japon] ; N. Miyasaka [Japon] ; K. Yamamoto [Japon] ; S. Kawai [Japon] ; T. Takeuchi [Japon] ; J. Azuma [Japon]Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
004185 (2007) Daisuke Noguchi [Japon] ; Daiko Wakita [Japon] ; Masaki Tajima [Japon] ; Shigeru Ashino [Japon] ; Yoichiro Iwakura [Japon] ; Yue Zhang [Japon] ; Kenji Chamoto [Japon] ; Hidemitsu Kitamura [Japon] ; Takashi Nishimura [Japon]Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a Th17-independent manner
004193 (2007) Norihiro Nishimoto [Japon] ; Jun Hashimoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Shinichi Kawai [Japon] ; Tsutomu Takeuchi [Japon] ; Norikazu Murata [Japon] ; Désirée Van Der Heijde [Pays-Bas] ; Tadamitsu Kishimoto [Japon]Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AffOrg.i -k "Université de Tokyo" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AffOrg.i  \
                -Sk "Université de Tokyo" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AffOrg.i
   |clé=    Université de Tokyo
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021